Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer/Washington U. Tie-Up Involves Reprofiling Of Existing Compounds

This article was originally published in The Pink Sheet Daily

Executive Summary

Under five-year collaboration, university researchers will have access to more than 500 Pfizer compounds and their clinical and preclinical data.

You may also be interested in...



NIH Royalties For Pfizer, AstraZeneca, Lilly Drugs Remain Open Question In Repurposing Initiative

With collaborative research agreement templates that include many of the details for a licensing agreement, royalties will be the major issue to be resolved if researchers develop new IP for one of the firm’s abandoned compounds.

NIH Center Would Seek To Boost “Repurposing” Of Shelved Drug Candidates

A proposed new center at the National Institutes of Health dedicated to speeding “translation” of biomedical research into therapies may focus initially on exploring new uses for drug candidates shelved by pharmaceutical firms, according to NIH Director Francis Collins.

NIH Center Would Seek To Boost “Repurposing” Of Shelved Drug Candidates

A proposed new center at the National Institutes of Health dedicated to speeding “translation” of biomedical research into therapies may focus initially on exploring new uses for drug candidates shelved by pharmaceutical firms, according to NIH Director Francis Collins.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel